title: Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
abstract: Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.
authors.affiliation: Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, England, UK.
authors.forename: J A
authors.initials: JA
authors.lastname: Harrington
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
mesh_terms: D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D000077143:Docetaxel; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy / Q000379:methods*; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D006728:Hormones; D043823:Taxoids; D000077143:Docetaxel